All In Biotech

Drug Trial Radar · NCT07727395

INtra-arterial AltEplase folloWing successfuL reperfusIoN After mEchanical Thrombectomy

Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 416 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

416

Planned (sponsor's estimate)

Start

Aug 1, 2026

Primary completion

Dec 31, 2028

Study completion Dec 31, 2028

Sponsor

Lead sponsor
115 People's HospitalGovernment (non-federal)
Sponsor type
Government (non-federal)
Collaborators
Ho Chi Minh City Stroke Association
First posted
Jul 27, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The NEWLINE trial is a multicenter, randomized, open-label, blinded endpoint (PROBE) trial evaluating whether adjunctive low-dose intra-arterial alteplase administered immediately after successful endovascular thrombectomy improves functional outcomes in adults with acute ischemic stroke due to anterior circulation large vessel occlusion. Eligible participants achieving successful reperfusion (eTICI 2b-3) within 24 hours of symptom onset will be randomized 1:1 to receive intra-arterial alteplase plus standard care or standard care alone. The primary outcome is excellent functional outcome (modified Rankin Scale score 0-1) at 90 days.

Conditions

  • Stroke, Acute Ischemic
  • Large Vessel Occlusion
  • Thrombectomy

Interventions

  • AlteplaseDrug

    Intra-arterial alteplase (0.225 mg/kg; maximum dose, 22.5 mg) administered immediately after successful endovascular thrombectomy in addition to best medical management.

  • Endovascular thrombectomyDevice

    Endovascular thrombectomy performed according to current international and local guidelines using approved endovascular techniques and devices.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Modified Rankin Scale at day 90Time frame: 90 days post treatment
  2. SAFETY OUTCOME: symptomatic intracerebral hemorrahge (sICH ) rate at 24 hours.Time frame: 24hours post EVT

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • Chau Doc General Hospital

    An Giang, Vietnam · Recruiting

  • Kien Giang General Hospital

    An Giang, Vietnam · Not yet recruiting

  • Can Tho Central General Hospital

    Can Tho, Vietnam · Recruiting

  • Da Nang Hospital

    Da Nang, Vietnam · Recruiting

  • Hanoi Medical University Hospital

    Hà Nội, Vietnam · Recruiting

  • Military Hospital 103

    Hà Nội, Vietnam · Not yet recruiting

  • Viet Tiep Friendship Hospital

    Haiphong, Vietnam · Recruiting

  • 175 Military Hospital

    Ho Chi Minh City, Vietnam · Not yet recruiting

  • People's Hospital 115

    Ho Chi Minh City, Vietnam · Recruiting

  • Thong Nhat Hospital

    Ho Chi Minh City, Vietnam · Recruiting

  • Thu Duc General Hospital

    Ho Chi Minh City, Vietnam · Not yet recruiting

  • University Medical Center

    Ho Chi Minh City, Vietnam · Recruiting

  • Hue Central Hospital

    Huế, Vietnam · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.